Providence Capital Advisors LLC Raises Position in Pfizer Inc. (NYSE:PFE)

Providence Capital Advisors LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 113,949 shares of the biopharmaceutical company’s stock after purchasing an additional 806 shares during the quarter. Providence Capital Advisors LLC’s holdings in Pfizer were worth $3,298,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. CreativeOne Wealth LLC lifted its stake in shares of Pfizer by 62.3% during the 3rd quarter. CreativeOne Wealth LLC now owns 117,673 shares of the biopharmaceutical company’s stock worth $3,405,000 after purchasing an additional 45,163 shares during the period. BNP Paribas increased its holdings in shares of Pfizer by 2.2% during the 3rd quarter. BNP Paribas now owns 192,456 shares of the biopharmaceutical company’s stock worth $5,573,000 after buying an additional 4,203 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of Pfizer by 528.7% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,668,833 shares of the biopharmaceutical company’s stock worth $106,176,000 after buying an additional 3,085,233 shares during the last quarter. Clifford Capital Partners LLC increased its holdings in shares of Pfizer by 9.6% during the 3rd quarter. Clifford Capital Partners LLC now owns 588,448 shares of the biopharmaceutical company’s stock worth $17,030,000 after buying an additional 51,703 shares during the last quarter. Finally, Blueshift Asset Management LLC increased its holdings in shares of Pfizer by 51.1% during the 3rd quarter. Blueshift Asset Management LLC now owns 48,001 shares of the biopharmaceutical company’s stock worth $1,389,000 after buying an additional 16,235 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.2 %

Shares of Pfizer stock opened at $25.83 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The business has a 50-day moving average of $27.97 and a 200-day moving average of $28.52. The company has a market capitalization of $146.38 billion, a PE ratio of 34.91, a P/E/G ratio of 0.83 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter last year, the company posted ($0.17) earnings per share. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.50%. Pfizer’s payout ratio is 227.03%.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on PFE shares. Barclays upped their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Wolfe Research assumed coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Sanford C. Bernstein assumed coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $32.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.